John Thompson - Anthera Pharmaceuticals CEO Director
Insider
John Thompson is CEO Director of Anthera Pharmaceuticals
| Age | 56 |
| Phone | 410 350 1839 |
| Web | https://www.anthera.com |
Anthera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.4196) % which means that it has lost $1.4196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.6885) %, meaning that it created substantial loss on money invested by shareholders. Anthera Pharmaceuticals' management efficiency ratios could be used to measure how well Anthera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Isabelle Lefebvre | Eyepoint Pharmaceuticals | N/A | |
| Adam Thomas | Synlogic | N/A | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| George Elston | Eyepoint Pharmaceuticals | 59 | |
| Christine MBA | SAB Biotherapeutics | 69 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| John CPA | Unicycive Therapeutics | 63 | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Piergiorgio Donati | AC Immune | 54 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| James Collins | Synlogic | 58 | |
| Alexander Klibanov | Pulmatrix | 75 | |
| Marie KoscoVilbois | AC Immune | 66 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Aidan Curran | Pulmatrix | N/A | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| Joshua Drumm | AC Immune | N/A | |
| Edward DVM | SAB Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 |
Anthera Pharmaceuticals Leadership Team
Elected by the shareholders, the Anthera Pharmaceuticals' board of directors comprises two types of representatives: Anthera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anthera. The board's role is to monitor Anthera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Anthera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anthera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bradley Esq, Sec | ||
| May Liu, Principal Accounting Officer, Compliance Officer and Sr. VP of Fin. and Admin. | ||
| Paul Adams, VP Compliance | ||
| Joshua Caldwell, Chief Officer | ||
| MBA MBA, Ex Chairman | ||
| Charles DSc, Advisor | ||
| Klara DickinsonEason, Advisor | ||
| John Thompson, CEO Director |
Anthera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Anthera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |